Changshan Song1, Pingfang Lu2, Weicheng Shi2, Guoqiang Sun3, Guangsuo Wang4, Xujie Huang2, Zheng Wang5, Zhigang Wang6. 1. Department of Thoracic Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630, China. 2. Department of Thoracic Surgery, Guangdong General Hospital of Armed Police Forces, Affiliated to Guangzhou Medical University, Guangzhou, Guangdong 510507, China. 3. Department of Thoracic Surgery, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524023, China. 4. Department of Thoracic Surgery, 2nd Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen, Guangdong 518020, China. 5. Department of Thoracic Surgery, 2nd Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen, Guangdong 518020, China. Electronic address: manuwangzheng@163.com. 6. Department of Thoracic Surgery, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524023, China. Electronic address: squarelu@163.com.
Abstract
PURPOSE: MicroRNA-622 has been proven down-regulated in many human malignancies and correlated with tumor progression. However, its role in esophageal squamous cell carcinoma (ESCC) is still unclear. The aim of this study was to explore the expression and function of miR-622 in ESCC. METHODS: Using quantitative RT-PCR, we detected miR-622 expression in ESCC cell lines and primary tumor tissues. The association of miR-622 expression with clinicopathological factors and prognosis was also analyzed. Then, the effects of miR-622 on the biological behavior of ESCC cells were investigated. At last, the potential regulatory function of miR-622 on E2F1 expression was confirmed. RESULTS: miR-622 was found to be down-regulated in ESCC tissues and cell lines. Decreased miR-622 expression was closely correlated with aggressive clinicopathological features and poor overall survival. Multivariate regression analysis corroborated that low level of miR-622 expression was an independent unfavourable prognostic factor for patients with ESCC. Up-regulation of miR-622 could significantly reduce ESCC cell proliferation, enhance cell apoptosis, and impair cell invasion and migration in vitro, while down-regulation of miR-622 showed opposite effects. Further, E2F1 was confirmed as a direct target of miR-622 by using Luciferase Reporter Assay. CONCLUSIONS: These findings indicate that miR-622 may act as a tumor suppressor in ESCC and would serve as a potential therapy target for this disease.
PURPOSE: MicroRNA-622 has been proven down-regulated in many humanmalignancies and correlated with tumor progression. However, its role in esophageal squamous cell carcinoma (ESCC) is still unclear. The aim of this study was to explore the expression and function of miR-622 in ESCC. METHODS: Using quantitative RT-PCR, we detected miR-622 expression in ESCC cell lines and primary tumor tissues. The association of miR-622 expression with clinicopathological factors and prognosis was also analyzed. Then, the effects of miR-622 on the biological behavior of ESCC cells were investigated. At last, the potential regulatory function of miR-622 on E2F1 expression was confirmed. RESULTS:miR-622 was found to be down-regulated in ESCC tissues and cell lines. Decreased miR-622 expression was closely correlated with aggressive clinicopathological features and poor overall survival. Multivariate regression analysis corroborated that low level of miR-622 expression was an independent unfavourable prognostic factor for patients with ESCC. Up-regulation of miR-622 could significantly reduce ESCC cell proliferation, enhance cell apoptosis, and impair cell invasion and migration in vitro, while down-regulation of miR-622 showed opposite effects. Further, E2F1 was confirmed as a direct target of miR-622 by using Luciferase Reporter Assay. CONCLUSIONS: These findings indicate that miR-622 may act as a tumor suppressor in ESCC and would serve as a potential therapy target for this disease.
Authors: Francesca Maria Orlandella; Raffaela Mariarosaria Mariniello; Peppino Mirabelli; Anna Elisa De Stefano; Paola Lucia Chiara Iervolino; Vito Alessandro Lasorsa; Mario Capasso; Rosa Giannatiempo; Maria Rongo; Mariarosaria Incoronato; Francesco Messina; Marco Salvatore; Andrea Soricelli; Giuliana Salvatore Journal: Br J Cancer Date: 2020-05-18 Impact factor: 7.640